4/A: MBX Biosciences Director Equity Grant Details

Steven L. Hoerter, a Director at MBX Biosciences, Inc., received a stock option grant with an exercise price of $24.74, vesting over one year.

Summary

• Steven L. Hoerter, a Director of MBX Biosciences, Inc., was granted stock options on November 6, 2025.
• The stock options have an exercise price of $24.74 per share.
• A total of 33,751 stock options were granted.
• These options are subject to a vesting schedule, with equal monthly installments over a one-year period from the grant date.
• The grant is contingent upon Mr. Hoerter's continued service to the company.
• This grant was adjusted downward to ensure the non-employee director's annual equity compensation for 2025 does not exceed $1,000,000 in aggregate grant date fair value, as per the company's Non-Employee Director Compensation Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily detailing a standard director equity grant with routine vesting terms and adherence to compensation policy limits.

Positives

• Director Hoerter received a significant stock option grant, aligning his interests with the company's performance.
• The grant is structured with a one-year vesting period, incentivizing continued service and commitment.
• The equity compensation is managed within the established Non-Employee Director Compensation Policy, indicating adherence to governance standards.

Negatives

• The grant was adjusted downward, suggesting potential limitations or a review of the initial compensation structure.
• The specific reason for the downward adjustment beyond the $1,000,000 cap is not detailed, which could imply internal compensation review or external market considerations.

Risks

• The vesting of options is contingent on continued service, meaning any departure before the vesting period is complete would result in forfeiture of unvested options.
• The value of the stock options is directly tied to the future performance of MBX Biosciences, Inc.'s stock price, which is subject to market volatility and company-specific risks.

Future Outlook

The stock options granted to Director Hoerter vest over one year, indicating a forward-looking incentive tied to continued service and company performance.

Management Comments

• The grant was adjusted downward to ensure the non-employee director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value.
• The grant will vest in equal monthly installments over a one-year period from the date of grant, subject to the non-employee director's continued services to the Company.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the biotechnology sector to align executive and board interests with shareholder value, especially during periods of development and growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The alignment of director compensation with company performance through stock options can positively influence long-term shareholder value.
• Employees: Standard director compensation practices can indirectly affect overall company compensation philosophy and resource allocation.
• Management: The grant reinforces the importance of director commitment and performance.

Next Steps

• Director Hoerter will receive monthly vesting of stock options over the next year.
• Continued service by Director Hoerter is required for full vesting of the granted options.

Key Dates

Keywords

MBX Biosciences, Steven L. Hoerter, Director Compensation, Stock Options, Equity Grant, Vesting Schedule, SEC Form 4, Beneficial Ownership